Emergent partnered with the USG to supply the nation’s only approved anthrax vaccine, BioThrax® (Anthrax Vaccine Adsorbed). Emergent has gradually grown from a one site, one product company to ...

The US Department of Defense (DoD) has awarded a procurement contract worth up to $235.8m to Emergent BioSolutions for an indefinite-delivery and indefinite-quantity (IDIQ) supply of BioThrax.

Emergent’s key Biodefense product, BioThrax, is the sole vaccine approved by the FDA for pre-exposure prophylaxis and post-exposure prophylaxis of anthrax disease. In the past year, shares of ...

is a biopharmaceutical company focused on protecting and enhancing life by developing and manufacturing vaccines and antibody ... product revenues from sales of BioThrax to the United States ...

The firm's products include ACAM2000, BioThrax, Raxibacuma, Vaxchora, and VIGIV. Its business units include Vaccines and Anti-Infectives, Antibody Therapeutics, Devices, and Contract Development ...

StockNews.com cut shares of Emergent BioSolutions (NYSE:EBS – Free Report) from a buy rating to a hold rating in a research ...